-
Ex-F1 driver turned Paralympic champion Zanardi dies
-
In Vietnam, Japan PM vows more effort to keep Asia 'free and open'
-
Humpback whale stranded in Germany released into North Sea: media
-
Japan PM meets top Vietnam leaders in Hanoi
-
Spirit Airlines begins 'wind-down', cancels all flights
-
Japan PM to meet top Vietnam leaders in Hanoi
-
Raisin moonshine banned in Iran enjoys resurgence in New York
-
Lebanon says 13 killed in Israeli strikes in south
-
No.1 Korda charges into share of LPGA Mexico lead
-
Young fires 67 to seize commanding PGA lead at Doral
-
US appeals court temporarily halts mail delivery of abortion pill
-
Joy for Norris in Miami as McLaren end Mercedes run
-
Leclerc offers hope to Ferrari fans in Miami
-
US to withdraw about 5,000 troops from Germany
-
'No going back' for Colombia's workers as the right eyes return
-
Norris on sprint pole as McLaren shine again
-
Venezuelan protesters call government wage hike a joke
-
Leeds beat Burnley to virtually secure Premier League survival
-
Gridlock as pandemic treaty talks fail to finish
-
S&P 500, Nasdaq end at fresh records on tech earnings strength
-
Immersive art: museum-goers in bikinis dive into Cezanne
-
Gaza activists disperse after flotilla halted by Israel off Crete
-
US sanctions are 'collective punishment,' says Cuba during May 1 marches
-
Delhi end slump with team-record chase against Rajasthan
-
Trump says will raise US tariffs on EU cars to 25%
-
AI actors and writers not eligible for Oscars: Academy
-
Rebels take key military base in Mali's north
-
ExxonMobil CEO sees chance of higher oil prices as earnings dip
-
Leclerc on top for Ferrari ahead of Verstappen and Piastri
-
Trump says 'not satisfied' with new Iran proposal
-
After Madonna and Lady Gaga, Shakira set for Rio beach mega-gig
-
Trump says will raise US tariffs on EU cars, trucks to 25%
-
Godon raises game to take Romandie stage and revenge over leader Pogacar
-
Celtic's O'Neill expects no let-up from Hibs despite fans' feelings
-
Pope names former undocumented migrant as US bishop
-
Javelin star Kitaguchi teams up with Czech legend Zelezny
-
Sawe sub-2hr marathon captured 'global imagination' says Coe
-
King Charles gets warm welcome in Bermuda after whirlwind US visit
-
Sinner shines to beat Fils, reach Madrid Open final
-
UK court clears comedy writer of damaging transgender activist's phone
-
Was LIV Golf an expensive failure for Saudis? Not everyone thinks so
-
Coe hails IOC gender testing decision
-
McInnes wants Tynecastle in 'full glory' for Hearts title charge
-
McFarlane says troubled Chelsea still attractive to potential managers
-
Man Utd boss Carrick relishes 'special' Liverpool rivalry
-
Baguettes take centre stage on France's Labour Day
-
Spurs must banish 'loser' mentality despite injury woes, says De Zerbi
-
Arsenal must manage emotions of title race says Arteta
-
Nepal temple celebrates return of stolen Buddha statue
-
US Fed official says rate hikes may be needed if inflation surges
Ketamine pill treats depression without psychedelic effects: study
A new pill that slowly releases ketamine could treat people with severe depression without giving them the psychedelic side effects of the often-misused drug, early trial results suggested on Monday.
First developed in the 1960s as an anaesthetic, ketamine's hallucinogenic and dissociative effects led to it becoming a party drug dubbed "Special K".
However, mounting research has demonstrated that ketamine is effective for the roughly quarter of people suffering from depression who see little benefit from common anti-depressant drugs.
In many countries, ketamine has been prescribed for depression for years.
US billionaire Elon Musk told CNN in March that he regularly uses a small amount of prescribed ketamine because it is "helpful for getting one out of the negative frame of mind".
The drug has long been administered intravenously in clinics, but more recently a nasal spray using a derivative called esketamine has increased in popularity.
Both can cause patients to have side effects such as dissociation, high blood pressure and an elevated heart rate.
There are also fears that medical use of the drug could slide into abuse.
The pill described in the journal Nature Medicine on Monday takes more than 10 hours to break down in the liver, lead study author Paul Glue told AFP.
"The really interesting feedback from patients is the lack of side effects -- no euphoria, no dissociation," said the researcher at New Zealand's University of Otago.
"I don't think these tablets would appeal to people who are abusing ketamine."
- Electro-shock alternative -
The phase 2 trial involved more than 270 people with depression who had previously tried an average of four different anti-depressant drugs.
More than half taking the ketamine pill went into remission for their depression, while 70 percent of the placebo group relapsed after 13 weeks, the study said.
Julaine Allan, an expert on mental health and addiction at Australia's Charles Sturt University who was not involved in the study, praised the trial while emphasising that more research is needed.
Ketamine does not work for everyone, and the "positive effects may wear off over time," she told AFP.
Michel Hoffmann, a psychiatrist at Geneva University Hospitals, said there is "real enthusiasm" in the medical community for ketamine's potential for treating depression.
"For patients who don't respond to conventional drugs, ketamine offers a way to avoid electro-shock therapy," he told AFP.
This last-resort treatment, which involves sending electric currents through the brain, has been proven to be effective.
But it can cause memory loss -- and some patients fear the procedure after seeing depictions of it in films such as "One Flew Over the Cuckoo's Nest".
- Fears of 'opioid style crisis' -
Some psychiatrists remain hesitant to prescribe ketamine for depression, fearing their patients could end up misusing the drug.
Last year, "Friends" actor Matthew Perry became the latest high-profile death from a ketamine overdose.
US police are investigating how Perry obtained the doses that caused his death -- he had reportedly not had a supervised infusion session for several days.
One potential benefit of quick-acting ketamine seen in previous research is that it could help patients considering suicide.
But there is "the plausible concern that the widespread use of ketamine might trigger a new opioid style crisis," Oxford researcher Riccardo De Giorgi said in a 2022 BMJ editorial.
By ridding ketamine of the side effects sought by some partygoers, the slow-release pill could alleviate some of these concerns.
There were still some side effects from the pill, the most common being headaches, dizziness and anxiety.
More research including phase 3 trials is needed before the drug can be reviewed by national medicine agencies, meaning it will be at least two or three years before patients could potentially access the pills, Glue said.
D.Schlegel--VB